BioSpace News Archive

Cemvita Factory, a carbon-negative company, today announced that it has received equity investment from Oxy Low Carbon Ventures to support the commercialization of new bio-engineered pathways that use CO2 as the feedstock for sustainable production of intermediate chemicals and polymers.

Inc. magazine revealed that NativePath, formally known as Lexicon Health, is No. 655 on its annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies.

PPG (NYSE:PPG) today announced that the PPG Foundation invested more than $1.5 million in 48 organizations to support educational and community sustainability programs throughout the U.S.

Onco360®, the nation’s largest independent Oncology Pharmacy, announced today that it was selected to be a specialty pharmacy network partner for Celgene’s new product Inrebic® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF)

On April 4, 2019, the daughter of a patient who died in a Pinellas County, Florida hospital sued St. Anthony’s Hospital, Inc. and Baycare Health System, Inc.

The Parliamentary Secretary to the Minister of Health, Pam Damoff, will announce new support from the Government of Canada for Canadians living with Autism Spectrum Disorder and those who care for them.

Online mail-order pharmacy selected for “Healthcare in America” documentary

Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today the acceptance of an oral late breaking presentation providing updated melflufen data from the Phase 2 pivotal OP-106 HORIZON study as well as two poster presentations at the 17th International Myeloma Workshop (IMW) meeting (September 12-15, Boston, Massachusetts, USA).

CVRx, Inc., a private medical device company, announced today that it has received Premarket Approval (PMA) from the United States Food and Drug Administration (FDA) to market its BAROSTIM NEO device for heart failure in the United States.

Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN).